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ABSTRACT 
 
Long term use of sugars can induce excess caloric intake and/or obesity. To 
evaluate the effects of sugar intake on different regions of the hypothalamus (the 
brain’s control center for energy homeostasis) we first developed and then 
evaluated a microscope-assisted dissection method. Because of the small size of the 
paraventricular nucleus, we validated the samples by measuring several hormones 
mainly synthesized in the paraventricular nucleus. These include 
corticotropin-releasing hormone, oxytocin, arginine vasopressin and thyrotropin 
releasing hormone. We measured the mRNA expression of each of these hormones 
using quantitative PCR and detected them principally in the paraventricular nucleus. 
We further evaluated the effects of various sugar solutions on the expression of 
several important hypothalamic neuropeptides because they play a pivotal role in 
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energy homeostasis. We provided Sprague Dawley rats 24 hour access to 15% 
solutions of glucose, fructose, sucrose or high fructose corn syrup. We then 
measured the expression of several neuropeptides in different hypothalamic regions, 
all of which were previously shown to be influenced by sugar consumption (mainly 
based on the results from a series of PCR arrays). Additionally, we measured 
plasma leptin, known for its close correlation with body fat mass. As expected, rats 
that had access to sugar solutions consumed less chow. However, rats with free 
access to sugar solutions maintained a similar amount of energy intake compared 
with control. Of the four sugars tested, only fructose decreased expression of 
cholecystokinin significantly, whereas glucose and sucrose significantly increased 
the expression of tumor necrosis α only in the paraventricular nucleus, not in the 
ventromedial nucleus or the lateral hypothalamic area. Fructose and sucrose 
decreased growth hormone expression in the ventromedial nucleus. Glucose 
increased dopamine receptor D1A expression in the paraventricular nucleus only. 
We conclude that 24 hour free access to different sugars can influence the 
expression of several hypothalamic neuropeptides in different ways and these 
changes are region dependent. Changes in the expression of these neuropeptides do 
not disrupt the total energy intake immediately but may contribute to the obesity 
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CHAPTER 1. SUGARS AND ENERGY CONTROL – A REVIEW 
Overview 
Obesity is spreading like a plague worldwide. As a result, the research to curb this 
trend is urgent. HFCS has taken over the food marketplaces as a sweetener for 
several years. Because the fructose content of HFCS is greater than that of sucrose, 
several authorities have speculated that it is this higher fructose intake that has 
caused the current obesity problem [1-3]. Energy balance is achieved only as the 
result of both central and peripheral regulators working together. As high sugar 
intake can induce obesity and metabolic symptoms, whether free access to sugar 
sweetened solutions also have the same consequences is seldom discussed. In fact 
it’s been known for years that long term access to sugar solutions can induce excess 
energy intake and overweight. We believe that if sugars induce obesity, they must 
have the ability of disrupting this system. The question is “How?”  
This review chapter describes the background about the basic characteristics of 
obesity as well as its possible causes and mechanisms. The review also summarizes 
the current evidence that shows how sugars, typically sugar solutions, affect the 
energy control in both peripheral and central aspects in an attempt to explain sugar 





Sugar and Obesity 
Obesity epidemic 
Obesity is a disease that is characterized by excess fat accumulation as well as a 
shift in metabolism. The body mass index (BMI) has been developed as a tool to 
help researchers quantify the degree of obesity [see Table 1]. According to World 
Health Organization (WHO), people with BMIs over 30.0 are classified as obese. 
By this definition, the obese population has nearly tripled in the US over the last 
forty years. Obesity has become a public health epidemic in America. 
Unfortunately, the obese population is still growing and predicted to reach around 
50% of total population in 2020 in US [4]. Furthermore, the obesity epidemic is not 
limited to the US. Modernization has been accompanied by increasing rates of 
obesity worldwide. The reason that obesity is a concern is not only because obesity 
can affect mobility and ease of movement, but also due to the close association 
between obesity with various comorbidities, such as those illustrated below in 
Figure 1. It should be noted that most of these are leading causes of death in the US. 
As a result a great deal of effort and money has been spent on developing obesity 
treatments. Although obesity is one of the most preventable health problems, to 




for obesity treatment. Reduced physical activity and increased energy intake are 





Table 1 BMI and obesity 
BMI Classification 
< 18.5 underweight 
18.5–24.9 normal weight 
25.0–29.9 overweight 
30.0–34.9 class I obesity 
35.0–39.9 class II obesity 
≥ 40.0 class III obesity 







There are several types of obesity, of which central obesity is the most harmful. 
Central obesity is characterized by excessive abdominal or ectopic fat accumulated 
around the stomach and abdomen. The "pot belly" or "beer belly" are terms that are 
often used to refer to central obesity. It needs to be noted that central obesity is not 
confined to obese subjects. It is proposed that it is the body fat instead of body 
weight that is the key to evaluating health risks related to obesity. One human study 
showed that fructose-sweetened beverages increased visceral adiposity in 
overweight/obese subjects, but glucose-sweetened beverages did not[5]. Generally 
speaking, obese population are at a higher risk of motality[6], therefore we will not 







Figure 1 Obesity related diseases.  
Obesity is closely associated with various comorbidities, including cancer, 
hypertension, cardiovascular diseases, sleep apnea and gall bladder disease, most of 






The body has its delicate mechanism to keep energy balance so as to maintain body 
weight. Normally, the body matches energy expenditure to energy intake. Any 
undesirable factors that disrupt this balance can lead to changes in body 
composition [see Figure 2]. These are often accompanied with an increase of risks 
of diseases. Animals compensate for variations in caloric content by adjusting 
intake, within limits. Adolph was the first to report that dilutions of food greater 
than 50 % resulted in weight loss [7]. By comparison, enriched diets (by increasing 
its caloric density) promote increased caloric intake [8-10]. From the evolutionary 
viewpoint, protection from starvation by storing fat has a great advantage when 
food is scarce. When food is abundant, this “advantage” becomes a disadvantage. 
Although the body has multiple mechanisms to maintain energy balance under 
normal conditions, the long-term use of high energy containing foods (including 
high sugar or high fat diets) can disrupt energy balance. However, different from 
the sugar enriched diet that can be considered as calorie dense diet, whether free 








Figure 2 Scheme of energy balance.  
The body has its delicate system that matches energy expenditure to energy intake. 
Any undesirable factors that disrupt this balance can lead to changes in weight gain 






Fructose hypothesis debate 
There are many factors that can cause obesity. These include some specific diseases 
like schizophrenia and downs syndrome as well as genetic mutations like FTO gene 
mutation, leptin gene or leptin receptor gene mutations. Modernized lifestyle 
including reduced physical activity, sedentary lifestyle or dietary factors especially 
high sugar diet and high fat intake that can also promote obesity. Because the 
obesity rate has risen to epidemic proportions it is likely that both genetic and 
environmental factors are responsible.  
It is well known that high fat diet can lead to obesity. However, the fact that 
years of promotion of low fat or fat free products failed to change the obesity 
increasing trend shifted people’s attention to high sugar diet[2]. Low carbohydrate 
intake is comparably or even more effective when compared with low fat intake in 
promoting weight reduction for up to one year [11, 12]. The total consumption of 
sweeteners has been increasing slowly for years. HFCS has replaced over half of 
the sucrose over the past few decades. Taken these factors together, the fructose 
hypothesis was generated: high intake of HFCS or fructose has caused the current 
obesity epidemic [1-3]. The fructose hypothesis has been bantered about for years. 
Although the expanding obese population is well correlated with increasing HFCS 




obesity did not stop or slow down accordingly. Many people argue that HFCS is 
similar to sucrose and intake of either sugar has little relationship with the obesity 
epidemic. They have proposed that the obesity epidemic is probably just a result of 
excess energy intake instead of specific sugar intake [13, 14]. On the other hand, 
several researchers have continued to propose that fructose or HFCS are 
responsible for the obesity epidemic [15-17]. They note that even though the total 
HFCS intake has dropped since 2000, the intake of fructose is still at a high level, 
which represents approximately 10% on average of total calories consumed [18]. 
Second, many animal studies have shown that high fructose diets have high 
potential to induce insulin resistance, hypertriglyceridemia and metabolic 
syndrome [19-21]. These symptoms are frequently observed in obese people [22]. 
In fact, several researchers even use high fructose diets to generate obese or insulin 
resistance models for study [23-25]. Third, fMRI results from human subjects 
showed that fructose has little effect on the suppression of food intake signals 
compared with glucose[26].  
The data from human studies are limited and inconclusive. Differences in the 
design of animal studies may also be responsible for inconsistent results. High 
intakes of sugars by adulterating the diet [21, 27, 28] or by gavage [29] under 




typically consume sugars voluntarily. On the other hand, some foods with high 
sugars, many types of fruits for example, are associated with improved metabolic 
parameters [30, 31]. This is maybe because the natural biological matrix may have 
the ability of buffering the sugar effects [32]. At this point, studying the free access 
to sugar solutions are more helpful in understanding the effect of sugars on the 
current obesity epidemic. 
 
Sugar induced obesity 
Recently two questions have been put forward [33]: first, is there evidence that 
excess energy intake from sugars is more detrimental than excess energy in other 
forms? Second, is there evidence that specific sugar(s) can promote excess energy 
intake? Calorie dense foods can increase energy intake and cause obesity, but 
controlled high fat food can even decrease body weight and improve several 
metabolic parameters [34]. From this point of view, since excess sugar up-taken 
can also be stored as fat, high sugar diet induced obesity should also be controlled 
by restriction or alternate dieting. However, sugar solutions are not considered as 
calorie dense food if they are freely available. Therefore, in this review we will 




sugar solutions on the energy control, which is helpful to answer the second 
question. 
HFCS intake has increased over 1000% between 1970 and 1990 [1]. Our 
bodies have several control mechanisms to limit the adverse effects of glucose 
intake. Different from glucose, fructose (with its limited physiological controls), is 
much easier to convert to triglycerides. This is probably an evolutionary result due 
to the ready availability of glucose from traditional foods. Although much evidence 
has shown that fructose has many adverse effects on our health such as generation 
of the toxic advanced glycation end-products and causing chronic diarrhea or other 
functional bowel disorders [35], how sugars affect energy balance needs deeper 
investigation. One early study showed that short term of high fructose gavage did 
not show apparent toxic symptoms and the immediate effect of fructose is the 
glycogenesis in both liver and muscles [36]. Moderate fructose supplementation 
over 4 weeks increases fasting triglyceride, VLDL-triglyceride, lactate, leptin and 
glucose without any significant changes in body weight, insulin resistance, 
hepatocellular lipids and myocellular lipids [37]. However, another research group 
used high glucose or fructose diet on the overweight and obese human subjects and 
extended the treatment for up to ten  weeks [5]. They found that both sugars 
induced increased weight gain, however, the visceral adipose volume was only 




Most researches are focusing on the comparison between fructose and glucose. 
Sucrose is broken down into the monosaccharides glucose and fructose by sucrase 
in the intestine before absorption. HFCS is a mixture of glucose and fructose as well 
as some polycose. Since it’s easier to regard sucrose and HFCS as just an 
intermediate between glucose and fructose, few reports include them into research 
for comparison. Sucrose and fructose are naturally biosynthesized sugars widely 
found in plants and fruits. Because of economic reasons, HFCS has replaced most 
of the sucrose as a food additive. It is argued that the health issues caused by HFCS 
are mainly attributed to its fructose content. In fact, many popular brands of soft 
solutions use either 65% or 55% fructose containing HFCS [38] and the ratio of 
fructose to glucose varies from around 1 to 1.5 [39]. HFCS or fructose/glucose 
mixture is different from sucrose in many ways. For example, HFCS is more 
preferable than the simple glucose and fructose mixture because of the existence of 
some polycose [40]. Fructose can facilitate glucose absorption and the fructose in 
excess of glucose can lead to malabsorption [41]. Subjects with consumption of 
HFCS-sweetened beverages had higher fructose absorption and glucose 
bioavailability than those with sucrose-sweetened beverages [42]. Fructose/glucose 
mixture has more potential to generate hepatic uric acid and triglycerides and cause 
fatty liver than sucrose. By contrast, sucrose can increase more TNF-α expression 




mixture[43]. The effect of sugars with different chemical structures on gut 
microbiota may also be different. There is a possibility that different 
gastrointestinal effects may result from consuming these different sugars. A recent 
report even showed that non-calorie sweeteners can induce glucose intolerance by 
changing the gut microbiota[44]. All these suggest that studying the effect of 
individual sugar forms is necessary. This also points to a follow-up question that 
whether or not these differences can affect the central neural system (CNS) and lead 
to changes in energy homeostasis.   
It has been known for years that two months’ ad libitum access to sugar 
solutions (glucose, sucrose or fructose), can induce excessive caloric intake, weight 
gain and/or even obesity [45-47]. Further studies showed that long term free access 
to HFCS (55 % fructose), fructose,sucrose or glucose solutions can all induce 
overweight and obesity after months’ exposure [5, 48-50], though fructose drink 
seem to be more effective to increase visceral fat. Under normal conditions, energy 
balance is maintained: the body matches energy expenditure and energy intake [51]. 
However, this system of energy control seems to have bias under specific 
“emergent circumstances” which facilitates excess energy intake [52]. Some factors, 
sugar solutions when freely accessible for example, can apparently disrupt the 





Sugars and peripheral metabolic controls 
Cooperating with the hypothalamus, peripheral energy status signals play an 
important role in energy homeostasis (see Figure 3). A list of well-studied 
peripheral signals is shown in Table 1. Presented below are several of these that 
were shown to be affected by sugar intakes based on previous work (for example, 





Table 2 A list of peripheral signals 





CCK   




































Figure 3 Signals in regulation of food intake.  
The dietary sugars affect many peripheral tissues including stomach, intestine, liver, 
pancreas and adipose tissue, all of which can produce their distinct circulating 







Fructose and hepatic glucose metabolism 
Dietary fructose is absorbed slower than glucose, making it likely that the effect of 
the high fructose load to the liver is buffered [36]. Fructose was shown to increase 
glucose uptake [54], glucose phosphorylation [55, 56] and glycogen synthesis [57] 
by increasing synthase I activity [36, 58]. Intravenous administration of high 
fructose can significantly reduce the activity of synthase I and increase 
phosphorylase a in the liver [59]. However, even high dietary fructose intake cannot 
reach this level in the bloodstream. Around 38% of absorbed fructose will be stored 
as glycogen in liver and 37% in the muscle, which is significantly higher than 
glucose intake [36]. The extracted fructose also facilitates gluconeogenesis. The 
fructose induced gluconeogenesis is partly due to the increased glucocorticoid 
receptor activity via the hypothalamic AMPK activation [60]. In contrast, dietary 
fructose intake seems to contribute little to the circulating glucocorticoids [61]. 
Therefore, the increased GR activity may be caused by fructose induced 11β HSD1, 
which is capable of mediating intracellular glucocorticoid [62]. Although fructose 
and glucose can quickly increase circulating fructose or glucose concentrations [26], 
one day treatment of these sugars has only a mild effect on circulating glucose 
levels [63]. All of these show that short term fructose intake is not able of causing 




malabsorption [41], it’s speculated that long term access to HFCS or sucrose can 
facilitate sugar absorption and therefore may be more harmful than pure sugar 
intakes. 
 
Sugars and triglycerides 
Fructose and glucose are two of the main sugar sources in the human diet. While 
glucose can easily pass through liver and be metabolized in nearly every type of 
cells, fructose metabolism is performed mainly in liver. Fructolysis quickly 
produces the hepatic trios-phosphates. Most of the trios-phosphates are converted 
into glucose and lactate. Another part of trios-phosphates are subjected to de novo 
lipogenesis (see Figure 4). Quick metabolism of a high amount of fructose can lead 
to an overburdening of the liver, increasing the risk of many hepatic diseases and 
comorbidities, including non-alcoholic fatty liver disease, steatohepatitis, ectopic 
obesity and hepatic insulin resistance [64]. Decreased very low density lipoprotein 
(VLDL) triglyceride clearance, an increased VLDL-triglyceride secretion as well as 
de novo lipogenesis together contribute to fructose induced metabolic syndrome 
[64-67]. With fewer metabolic controls, fructose can increase circulating 




Mice lacking fructokinases (isoform A and C) fail to develop fructose-induced 






Figure 4 Different hepatic metabolism of fructose and glucose.  
Fructokinase is more efficient to metabolize fructose than what glucokinase does 
for glucose. As a result, glucose can easily pass through liver and be metabolized in 
nearly every type of cells, whereas fructose metabolism is mainly performed in the 
liver. Although both share many steps, fructolysis can enter the triglyceride 





VLDL carrying triglycerides was thought to cause the fructose induced 
hypertriglyceridemia[69]. Apo lipoprotein C3 (Apo C3) is an important surface 
component of VLDL. Because fructose can quickly increase circulating 
triglycerides, Apo C3 was proposed as a key factor in promoting fructose-induced 
hypertriglyceridemia. Our lab recently found that hepatic Apo C3 mRNA 
expression from fructose intake alone did not change significantly compared to the 
control. On the contrary, hepatic Apo C3 expression was increased by around 250% 
in glucose, sucrose and HFCS groups [70]. This suggests that Apo C3 expression 
level is not sufficient to predict the ability of VLDL-TG secretion. Apo B may be 
another determinant which needs further investigation. A supporting report showed 
that consumption of fructose-sweetened instead of glucose-sweetened beverages 
(25% of energy requirement) in addition to ad libitum diet could cause postprandial 
hypertriglyceridemia and increased circulating LDL and Apo B levels in young 
men and women [71]. 
 
Sugars and glucocorticoids 
The parvocellular cells of the PVN secrete CRH which stimulates the pituitary 
gland to release adrenocorticotropic hormone (ACTH) into circulation. ACTH 




and corticosterone in rodents. The glucocorticoids then suppress the PVN and 
pituitary to form a feedback loop. In mammals, the adrenal cortex synthesizes 
mineralocorticoids and glucocorticoids. Circulating levels of glucocorticoids vary 
widely, from low levels during sleep to relatively high levels during severe stress. 
These hormones are tightly bound to a high-affinity corticosteroid-binding globulin 
(CBG) and albumin. As a result only around 5% of glucocorticoid is free, while the 
inert glucocorticoid level is higher. The glucocorticoids pass through the cell 
plasma membrane to take effect by binding to the mineralocorticoid receptor (MR) 
or the glucocorticoid receptor (GR). Once activated, GR or MR translocates to the 
nucleus and binds to the regulatory regions of target genes to affect downstream 
pathways. Glucocorticoids can function to increase glucose levels, reduce 
inflammatory reactions and promote cell differentiation.  
Glucocorticoid induced obesity, especially visceral obesity, is well 
documented. Bilateral adrenalectomy can lead to body weight loss by reducing 
glucocorticoids [72]. Glucocorticoid induced obesity is clinically manifested as 
Cushing’s syndrome [73]. Surprisingly, circulating plasma glucocorticoids are 
stable in simple obese patients. As a result local glucocorticoid concentrations are 
proposed as a key contributor to the obesity development, which is mainly 




that catalyzes the inter-conversion of active and inactive glucocorticoids (e.g. 
cortisol to cortisone in humans and corticosterone to hydroxycorticosterone in rats). 
The activity and reaction direction of 11β-HSD1 varies by cell types. In intact 
mature cells, 11β-HSD1 primarily acts as an oxoreductase to facilitate active 
glucocorticoid generation in both hepatocytes [75] and mature adipocytes [76]. 
11β-HSD1 is abundantly expressed in liver, adipose, gonadal and central nervous 
system tissues. Applying the specific adipose 11β-HSD1 inhibitors has been 
proposed to be a novel approach to the treatment of central obesity [77]. Both 
overexpression and knockout of adipose 11β-HSD1 showed that 11β-HSD1 
activity is positively associated with metabolic syndrome [78-80]. Similarly, 
Zucker obese rats that were treated with carbenoxolone (an hepatic 11β-HSD1 
inhibitor) had improved lipid profiles [81]. Knockout of hepatic 11β-HSD1 mice 
resist 1-dehydrocorticosterone induced metabolic syndrome as do the global 
11β-HSD1 knockout [82]. Several 11β-HSD1 inhibitors have been and are being 








Figure 5 Intracellular glucocorticoids and obesity.  
11β-HSD1 is the critical enzyme that can increase the level of active 
glucocorticoids by regenerating cortisol in humans and corticosterone in rats. The 
increased intracellular level of glucocorticoid is involved in development of obesity, 





It is well known that obesity is associated with high level of 11β-HSD1 in 
adipocytes. Fructose can increase 11β-HSD1 in adipocytes [67, 83] and quickly 
increase hepatic 11β-HSD1 expression after 24 h exposure but decrease its 
expression after one week [67]. However, the difference between sucrose or HFCS 
and their controls failed to reach statistical significance. Compared with glucose, 
HFCS and fructose also slightly reduced 11β-HSD1 mRNA expression in the 
ventromedial hypothalamus [84]. From this point of view, the fructose component 
has more potential in causing obesity and/or metabolic syndrome. Consistent with 
these findings, fructose-sweetened beverages is more effective than glucose to 
increase visceral adiposity in overweight/obese subjects [5]. 
 
Communications between CNS and peripheral tissues 
There is a close interaction between CNS and peripheral tissues via circulating 
signals as well as through the vagus nerve. The hypothalamus can directly sense 
some peripheral signals including insulin, leptin, glucocorticoid and glucose. The 
nucleus tractus solitarius (NTS), located at the hindbrain, is another important hub 
that integrates the peripheral information mainly from the vagus nerve and then 
relays the signals to the hypothalamus and other brain areas that control feeding 





Effects of sugar intake on CNS 
Central control of food intake - Hypothalamus 
The hypothalamus, a brain structure that is located below the thalamus, contains a 
number of nuclei that control a variety of functions. The hypothalamus links the 
nervous system to the endocrine system via the pituitary gland. In response to 
various types of stimuli the hypothalamus synthesizes and secretes a series of 
neuro-hormones which in turn stimulate or inhibit the secretion of pituitary 
hormones that regulate various endocrine glands and organs. Through this 
mechanism, the hypothalamus can control body temperature, fatigue, sleep, 
circadian cycles, hunger and thirst. The hypothalamus can also communicate 
neuronally with other part of the brain areas to control specific behaviors.  
The hypothalamus is the body’s energy control center. Several hypothalamic 
neuropeptides have been identified to play essential roles in energy control. The 
hypothalamus is composed of various neurons involved in a complicated neuronal 
network. The arcuate nucleus (ARC) was early proposed as the “first order” control 
of hypothalamus. It senses peripheral signals in order to control food intake by 
activating the “secondary control” areas that include the paraventricular nucleus 




(LH). This belief is challenged by two phenomena: 1st, diet induced obesity can 
cause ghrelin resistance in ARC but not PVN [86] ; 2nd, conditional knockout of 
leptin receptors from POMC [87, 88] and/or agouti related peptide (AGRP) neurons 
[89] can only cause mild obesity, whereas pan-hypothalamic leptin receptor 
deletion lead to the severe obesity similar to that with global loss of leptin signaling 
[52, 90]. Therefore, we think different hypothalamic regions may be able of sensing 
the circulating signals in various ways. The current study is attempting to find out 
how different sugars affect energy control by regulating different neuropeptides in 







Figure 6 The classic model of hypothalamic control of food intake.  
The ARC of the hypothalamus is involved with both anorexic and orexic circuits 
containing many types of receptors including leptin receptors, insulin receptors and 
ghrelin receptors. The neurons expressing NPY and AgRP as well as neurons 
expressing POMC and CART) can receive the signals from the circulating 
hormones. They work cooperatively to activate PVN and VMH to inhibit food 
intake and inhibit this process to activate LH to increase food intake or vice versa. 
PVN, VMH and LH have their own complicated neuro-signals for further feeding 
behaviors. On the other hand, the hypothalamus can also sense the signals to control 





The ARC of the hypothalamus is involved with both anorexic and orexic 
circuits. The ARC, with its reduced blood brain barrier, can sense signals from the 
bloodstream quickly. NPY and AgRP are co-localized in ARC neurons, while 
pro-opiomelanocortin (POMC) and cocaine and amphetamine regulated transcript 
(CART) are co-localized in a distinct, but adjacent, subset of ARC neurons [91, 92]. 
Both types of neurons express leptin receptors [93] and insulin receptors [94]. This 
also explains the critical role of ARC in leptin signaling [95] and insulin signaling 
[96]. NPY is an orexigenic peptide. Loss of NPY can attenuate the obesity of ob/ob 
mice [97]. NPY deficiency does not affect feeding behavior[98]. This 
compensation may be attributed to the activation of other orexic neuropeptides in 
the absence of NPY. Melanocortin peptides including α-melanocyte stimulating 
hormone (α-MSH) are cleaved from POMC and functions by binding to a family of 
melanocortin receptors including MC3 and MC4 receptors [99]. Upon activation, 
α-MSH and CART act cooperatively to inhibit food intake, whereas NPY and 
AgRP inhibit this process and increase food intake. However, brief sugar intake did 
not change these neuropeptides in the ARC [63]. By contrast, different sugars have 
different effects on the activities of the hypothalamus, where appetite, motivation 
and reward processing functions are regulated [26, 100]. It has been known for 
quite some time that different hypothalamic structures and regions influence hunger 




control food intake [101]. The “Dual Center Hypothesis” was one of the most 
studied theses in 20th century neurophysiology. The PVN was added to this mix 
later, noting that there were differences in metabolic and behavioral controls of 
hunger [102]. PVN, VMH and LH have their own complicated neuro-signals for 
further feeding behaviors. For example, PVN and VMH control for satiety whereas 
LH controls for hunger [Figure 6]. To achieve this, the hypothalamus has 
complicated neuronal circuits with many redundant neuropeptides [Table 3]. 
Switching on and off of these neuronal signals is linked with specific feeding 
behaviors. Through this mechanism, the hypothalamus coordinates energy balance. 
Once the balance is biased, obesity and/or other energy disorders may occur. The 
hypothalamus can also sense energy status by communicating with the nucleus of 
the solitary tract (NTS). The NTS integrates peripheral information via the vagus 
nerve [85]. The hypothalamus interprets the collection of information and then 














Hypocretin 1 and 2/orexin A and B GLP-1  
Galanin CART 
Galanin like peptide Urocortin 1,2 and 3 
Noradrenaline IL-1β 
Endogenous opioids (β-endorphin, 











Although there is ample evidence detailing how sugars metabolize peripherally, 
the effects of sugars in the CNS are not well understood. Glucose increases the 
neuronal activities in the brain particularly the hypothalamus where appetite, 
motivation, and reward processing are regulated. Fructose has the opposing effect 
[100, 103]. Fructose intake altered hypothalamic liver X receptor (LXR)-α and 
LXR-β expressions, which play a role in regulation of carbohydrate and lipid 
metabolism[104]. Fructose can induce hypothalamic AMPK activation by 
disrupting the glucagon-like peptide-1 (GLP-1) pathway [105]. This induces 
hepatic gluconeogenesis due to increased corticosterone release [60]. Fructose 
intake affects the enzymes involved in the synthesis and degradation of 
hypothalamic endocannabinoids [27]. Fructose can also increase the expression of 
the endocannabinoid receptor 1 (CB1) [106]. The increased endocannabinoid 
pathway signaling can stimulate satiety.  
In summary, all of the above makes it clear that fructose can affect the CNS, 
particularly the hypothalamus in a way that facilitates excess energy intake. Under 
ab libitum conditions, the effects of HFCS or sucrose on the CNS remain unknown. 
Peripheral fructose can quickly reach the hypothalamus. The fructose transporter 
GLUT5 is found throughout the hypothalamus [26]. The initial ATP-consuming 




step of glucose metabolism. The rapid depletion of ATP causes a rise of AMP 
which further leads to ACC inactivation and downregulated malonyl-CoA [107]. 
Reduced malonyl-CoA causes increased expression of the orexigenic hypothalamic 
neuropeptides, and in that way stimulate food intake [108]. Surprisingly, the 
accumulated lactate converted from fructose decreases food intake [109]. However, 
only a small portion from dietary sugar intake can reach the brain, the effect of 
dietary sugar intake should not as effective as this kind intracereventricular 
administration. 
 
Recent advances in the sugars and CNS 
To better understand the effect of sugar intakes on the CNS under ad libitum 
conditions, we recently fed Sprague Dawley rats with different sugar solutions. 
Glucose, fructose, sucrose and high fructose corn syrup (HFCS) solutions were 
made available for 24 h. We then evaluated the expression of 84 genes in the 
hypothalamus of these animals using PCR array (see Figure 7). We found several 
hypothalamic neuropeptides were regulated differently by different sugars [63]. For 
example, hypothalamic CCK was downregulated in 24 h when rats had access to 
the fructose solution, whereas CCK was unchanged in 24 h when rats had access to 




respond differently to different sugars. These include RAMP3, TNF-α, TRH and 
CRH [63]. RAMP3 plays an important role in the transport and modulation of G 
protein-coupled receptors (GPCRs), but its involvement in energy control is not 
quite clear. Hypothalamic RAMP3 was found to be upregulated by glucose and 
downregulated by both HFCS and fructose. TRH, regulated by energy homeostasis 
[110], promotes catabolic metabolism by decreasing food intake and increasing 
locomotor activity, body temperature and oxygen consumption [111]. TRH 
expression is upregulated in rats given access to fructose. TNF-α is an important 
inflammatory chemokine that was also found to regulate food intake. Consumption 
of glucose, sucrose or fructose all resulted in an upregulation of TNF-α expression 
in the hypothalamus. CRH is an important hormone involved in the 
hypothalamic-pituitary-adrenal axis and is also a well-known anorexigenic 
neuropeptide. We recently found only HFCS can downregulated hypothalamic 
CRH compared with other sugars. Since the hypothalamus is composed of different 
functional regions, we set out to determine which region(s) of the hypothalamus 







Figure 7 PCR array assay of rat hypothalamus.  
We recently fed Sprague Dawley rats with different sugar solutions including 
glucose, sucrose, HFCS and fructose. The hypothalamus samples from different 
groups of rats were subjected to PCR array with primed 84 genes. Several 
hypothalamic neuropeptides were found to be regulated differently by different 
sugars including CCK, RAMP3, TNF-α. TRH, CRH, GH etc. 
 
Hypothesis 
In the current research, we hypothesize that: 
Sugar intake can affect these neuropeptides in a way that facilitates energy 
imbalance. These effects are restricted to specific hypothalamic regions 







Objective 1: To evaluate a microscope assisted method to accurately sample the 
specific regions of hypothalamus; 
Objective 2: To determine the mRNA distribution of several hypothalamic 
neuropeptides that are associated with energy control; 
Objective 3: To evaluate the varying effects of different sugars on the expression of 
several neuropeptides in regulation of energy balance; 
Objective 4: To understand the relationship between the sugar intake and adiposity 





CHAPTER 2. REGIONAL MRNA EXPRESSION OF SEVERAL 
HYPOTHALAMIC NEUROPEPTIDES USING A FAST AND EASY 
DISSECTION METHOD [84]  
Abstract 
The PVN plays an essential role in neuroendocrine regulation. Accurate sampling 
of the PVN is critical for any successful measurement of many of its unique 
characteristics. Here we report a microscope-assisted fast and easy method to 
dissect hypothalamic regions. We applied this method to sample PVN that was 
validated by measuring several hormones mainly synthesized in the PVN. These 
include CRH, OXT, AVP and TRH. We measured the mRNA expression of each of 
these hormones using quantitative PCR in samples dissected from the PVN. We 
then compared their abundance to that found in samples taken from nearby 
structures (the VMH and the LH). The expression of CRH, OXT, AVP and TRH in 
the PVN samples was significantly higher than those in the VMH or the LH. The rat 
to rat variation found in our PVN samples is a reflection of individual differences as 
well as sampling error. We believe that this method could dramatically reduce the 
sampling time needed to characterize small neural targets like the PVN. 
We have previously shown that several hypothalamic neuropeptides can be 




different functional regions, how and where these neuropeptides were affected by 
different sugars is unknown. The distributions of several of these neuropeptides 
were reported previously whereas most of them were not. The reported 
distributions of some neuropeptides were mainly based on northern blotting or 
histochemistry. Neither method is sensitive enough to detect low amounts of gene 
expression compared with quantitative real time PCR. In this chapter, we analyzed 
the regional mRNA expression of several neuropeptides in the microdissected 
hypothalamic samples from Sprague Dawley rats. This step is critical for us to 
continue measuring these neuropeptides in specific hypothalamic regions of rats 
fed with different sugars. The neuropeptides analyzed include NPY, AgRP, CCK, 
RAMP3, TNF-α, Drd1a, Adra2b, GH and 11β-HSD1. 
 Consistent with previous reports, CCK was mostly abundant in the PVN of the 
hypothalamus. Interestingly, RAMP3 expression was also much higher compared 
with that in the other two regions tested. NPY and TNF-α were uniformly expressed 
in the hypothalamus. AgRP was highly expressed in the VMH. Drd1a and Adra2b 
had the similar distribution patterns, i.e. both of them were mostly expressed in the 
PVN followed by VMH and LH. GH was only detected in the VMH and LH. 




at the highest level. Understanding the distribution of these neuropeptides is 





The PVN is an integral part of hypothalamus, located laterally adjacent to the upper 
part of the third ventricle. The PVN contains several regions, including the 
magnocellular and parvocellular regions, as well as different types of 
peptide-containing cells that project to many extra-hypothalamic sites. The PVN 
plays a critical role in the neuroendocrine system by synthesizing a variety of 
hormones including CRH [112], OXT [113, 114], AVP [114] and TRH [115, 116]. 
All of these peptides were previously found to be mainly expressed in the PVN. 
Specifically, CRH and TRH are mainly concentrated in the parvocellular region of 
the PVN [116, 117], whereas most of OXT and AVP are expressed in the 
magnocellular region of the PVN [117].  
CRH is an important regulator of the hypothalamus-pituitary-adrenal (HPA) 
axis. CRH stimulates the pituitary gland to release adrenocorticotropic hormone 
(ACTH) into circulation. Among other things increased ACTH activates the 
adrenal gland to release glucocorticoids. The glucocorticoids then suppress further 
CRH release so as to form a feedback loop often referred to as “the HPA axis”. The 
operation of the HPA axis is important in adaptive responses to stress [118], food 
intake control [119] and immunity system [120-122]. OXT and AVP are two other 




vasoconstrictor and plays a role in  birth delivery and lactation [123, 124]. AVP is 
critical in body fluid maintenance by promoting water reabsorption, but also 
increases vasoconstriction [124]. Another PVN secreted hormone TRH is regulated 
by energy homeostasis [110]. TRH promotes the catabolic metabolism by 
decreasing food intake and increasing locomotor activity, body temperature and 
oxygen consumption [111]. Interestingly, all these peptides participate in food 
intake control [111, 125-127], which support the view that the PVN is a “satiety 
center” [51, 128].  
Because of the physiological importance of the PVN in the hypothalamus, it is 
often sampled for molecular studies. Several investigators have used 
micro-puncturing or dissection techniques to sample the PVN or other specific 
hypothalamic regions [129-134]. However, the pretreatment of the samples 
including staining or immuno-labeling often takes a long time. That delay may 
compromise the RNA or protein quality for downstream applications. Here we 
employed CRH, OXT, AVP and TRH as markers to evaluate a fast and easy method 
to sample the PVN as well as VMH and LH of Sprague Dawley rats.  
After validation of this method, we further used it to measure several 
hypothalamic neuropeptides that had been reported to be affected by 24 hour sugar 




RAMP3, TNF-α, Adr2b Drd1a, GH and 11β-HSD1. We attempted to measure these 
neuropeptides in specific hypothalamic regions including PVN, VMH and LH. The 
well-studied ARC was not included in the current study. Because two important 
orexigenic neuropeptides NPY and AgRP which are mainly synthesized in ARC 
were not affected by 24 h exposure to sugar solutions [63]. We hypothesize that the 
neuropeptides will probably be affected where it was originally biosynthesized. In 
addition to the reported neuropeptides we also include the neuropeptides OXT [125, 
126], AVP [135, 136] and 11β-HSD1 [137], which also participate in the energy 
control based on previous research.  
Different hypothalamic regions have differing effects on the feeding behaviors 
[51]. Specifically PVN and VMH control satiety whereas LH controls hunger [101, 
102]. Recent research has identified many neuropeptides in these hypothalamic 
regions that play important roles in energy control. The current study was 
performed to determine the mRNA expression pattern of these neuropeptides in the 






Materials and Methods 
Animal treatment 
Eight experimental adult male Sprague-Dawley (CD strain) rats (Charles River 
Laboratories, Wilmington, MA) weighing approximately 300g were used. All 
animals were individually housed under a 12h light/dark cycle in a temperature 
controlled room (22 ±1°C). After 1 week acclimation, the rats were killed by slow 
replacement of air in a specialized chamber with pure CO2 followed by rapid 
decapitation and exsanguination. This method has been approved for use by the 
Panel on Euthanasia of the American Veterinary Medical Association as well as the 
UM IACUC. All procedures described herein are in compliance with the University 
of Maryland’s ACUC guidelines. At the time of sacrifice, the rat brain tissues were 
collected, snap frozen in isopentane/dry ice and stored at -80°C.  
Brain slicing 
The frozen brains were embedded using M1 embedding matrix (Lipshaw, 
Pittsburgh, PA). An IEC Minot Custom Microtome (Damon/IEC Division) was 
used for cryosectioning. The blade and antiroll plate were pretreated with 
RNaseZap® to remove any possibility of RNase contamination and cleaned with 
paper towel presoaked in DEPC-treated water. The brain was sliced according to 




each slice was 110 µM. The slices were carefully transferred to pre-cleaned slides 
(Fisher Scientific, Pittsburgh, PA) and then stored at -80 °C until sampled.  
Hypothalamic Dissection 
Hypothalamic dissection was carried out within one month after brain slicing. 
Because brain slice samples after standard staining can lead to RNA loss by 10% in 
as little as 30 minutes [138], ethanol dehydration was used in our experiment. 
Preliminary test showed that cresyl violet staining did not help much in 
distinguishing hypothalamic structures due to the thickness of our samples. As a 
result we employed three steps of ethanol dehydration without staining, i.e. starting 
with 95% ethanol for 30 sec, followed by 100% ethanol for 1min and then finally 
100% ethanol for at least an additional 1min.  
Before the slices were completely dried out, the PVN, the VMH and the LH were 
sampled with a sterile 23 G X 1” hypodermic needle (B-D PrecisionGlide, Franklin 
Lakes. NJ) under a light microscope (Figure 1). Six to seven brain slices were used 
for the PVN dissection. PVN sampling was initiated approximately at -1.30 mm 
behind Bregma (Paxinos & Watson, The Rat Brain in Stereotaxic Coordinates, 
Second Edition). VMH and LH samples were dissected starting at around -2.12 mm 
behind Bregma. VMH samples were approximately 1.5 mm thick while LH 




transferred into cold 1.5 ml eppendorf tubes. RLT lysis buffer (350 µl) that 
contained 10 μl β-ME per 1 ml Buffer RLT was added into each tube followed by 
30 sec vortexing to facilitate cell breakage and RNA release. RLT lysis buffer is 
strong enough to inactivate RNase according to the manufacturer’s protocol. The 







Figure 8 Scheme of locations of PVN, VMH and LH.  
The scheme gives the general location and the relative size of the areas of interest in 





RNA extraction and cDNA synthesis 
The tissue lysates were thawed in a 37℃ water bath until all the salts were dissolved. 
The lysates of VMH and LH were centrifuged (Eppendorf centrifuge model 5424) 
at full speed for 3 min to remove the cell debris, as per the manufacturer’s 
instructions (Qiagen RNeasy micro kit). The PVN lysates were not centrifuged. 
DNase I was used to remove any DNA which may affect the downstream 
applications. RNA quality was examined using a NanoDrop 2000 
spectrophotometer based on A260/A280 values. cDNA synthesis was carried out 
using iScript™ cDNA Synthesis Kit (Bio-Rad) following the manufacturer’s 
protocol. The cDNA products were stored at -20°C until used.  
Quantitative Real Time PCR  
The PCR reaction with iQ SYBR Green Supermix was carried out in two replicates 
using a CFX96 Bio-Rad system. RPLP1 or β-actin were used as reference gene. 
The program used for all PCR reactions was 95 °C for 3 min and 40 cycles of 95 °C 









Table 4 Primer sets for Chapter 2 
Primer Name sequences (5' to 3') Ta (℃) 
RPLP1 sense GAAGAATCCGAGGATGACA 51 
RPLP1 antisense  CAGGTTCAGCTCTTTATTGG 
β actin sense TGTCACCAACTGGGACGATA 60 
β actin antisense GGGGTGTTGAAGGTCTCAAA 
11β-HSD1 sense GTGTCTCGCTGCCTTGAAC 55 
11β-HSD1 antisense AGTGGTCTGTGTGATGTGATTG 
OXY sense ACCCTGAGTCTGCCTTCT 54 
OXY antisense ATGGGGAATGAAGGAAGCG 
AVP sense ACCTCTGCCTGCTACTTC 53 
AVP antisense ACACTGTCTCAGCTCCAT 
NPY sense AATGAGAGAAAGCACAGAAA 46 
NPY antisense AAGTCAGGAGAGCAAGTT 
AgRP sense GAGTTCTCAGGTCTAAGTCT 49 







The Ct mean value from ribosomal protein large P1 (RPLP1) [139] or β actin 
[62] was used as the reference gene as before. All values were expressed as means ± 
SEM. Outlier data was removed using Dixon's Q test. Student’s t tests were applied 
to 2−𝛥𝛥𝛥𝛥𝑡𝑡 values to determine significance between groups using JMP Pro 10.0.2. P 
values less than 0.05 were considered statistically significant.  
 
Results 
Quality of samples 
Twenty four RNA samples extracted from the rat brains had good qualities 
evidenced by 260/A280 >1.8 (see Table 5). The melting curve confirmed the 






Table 5 260/A280 values of the twenty samples from of PVN, VMH and LH 
Labels PVN VMH LH 
A1 1.94 2.10 2.06 
A2 2.13 2.14 2.07 
A3 2.13 2.09 2.08 
A4 2.12 2.11 2.06 
B1 2.19 2.09 2.04 
B2 1.97 2.10 1.81 
B3 2.09 2.08 2.06 







Expression of PVN markers 
The expression of the PVN markers - CRH, OXT, AVP and TRH were significantly 







Figure 9 Expression of PVN markers.  
(A) Expression of CRH mRNA in the PVN, VMH and LH. Expression of CRH 
mRNA in the PVN is significantly higher than that in VMH and LH. (B) Expression 
of OXT mRNA in the PVN, VMH and LH. Expression of OXT mRNA in the PVN 
is significantly higher than that in VMH and LH. (C) Expression of AVP mRNA in 
the PVN, VMH and LH. Expression of AVP mRNA in the PVN is significantly 
higher than that in VMH and LH. (D) Expression of TRH mRNA in the PVN, VMH 
and LH. Expression of TRH mRNA in the PVN is significantly higher than that in 
VMH and LH. 




Distribution of other neuropeptides in the hypothalamus 
CCK was expressed in the PVN at a higher level than that in the VMH or LH. 
RAMP3 expression was also much higher compared with that in other two regions 
tested. NPY and TNF-α were uniformly expressed in the hypothalamus. AgRP was 
highly expressed in the VMH. Drd1a and Adra2b had the similar distribution 
pattern, i.e. both of them were mostly expressed in the PVN, and following is VMH 
and LH. GH was only expressed in the VMH and LH. 11β-HSD1 was abundantly 
expressed in the hypothalamus. Specially, 11β-HSD1 is mostly expressed in the LH 







Figure 10 Expression of several hypothalamic neuropeptide mRNA in the 
hypothalamus.  
(A) CCK was mainly expressed in the PVN of the hypothalamus. (B) RAMP3 
expression was also much higher compared with that in other two regions tested. (C) 
NPY was uniformly expressed in the hypothalamus. (D) AgRP was highly 
expressed in the VMH. (E) TNF-α were uniformly expressed in the hypothalamus 
(F-G) Drd1a and Adra2b had the similar distribution patterns, i.e. both of them were 
mostly expressed in the PVN followed by VMH and LH. (H) GH was only detected 
in the VMH and LH. (I) 11β-HSD1 was widely detected in the hypothalamus with 
its expression in the LH at the highest level. 














Two methodological issues encouraged us to develop the alternative method 
described above. First, many labs have applied staining (typically cresyl violet) to 
identify the PVN [140-142]. However, brain slices after standard staining can lose 
as much as 10% of its RNA within 30 minutes [138]. Here we have demonstrated 
that the micro-dissection of brain slices can be performed under a microscope 
without staining. Additionally, this method allowed us the use of thick slices for 
dissection/sampling and that way minimized steps that could have affected the 
structure or intracellular molecules for downstream analysis. Secondly, 
immunohistochemical methods have been used to identify peptides within a known 
anatomical region such as the PVN [141, 143]. However, this technique is both 
costly and labor-intensive. As an alternative, we have sampled regions of the PVN 
and verified the accuracy by amplifying mRNA that is known to be localized only 
in the PVN. Our findings confirmed that we have been able to sample the PVN, as 
CRH, OXT, AVP and TRH messages were not measured to any extent in samples 
of the VMH or LH.   
Another way to further validate the PVN samples is to examine mRNAs that 
wouldn’t be in PVN but would be in surrounding areas. We examined GH that was 




should be noted that a similar validation was not performed on VMH and LH 
samples. When compared with the PVN, these two regions are much larger and 
anatomically distinct, making it unnecessary to further examine if they were 
accurately dissected.  
Consistent with previous report, CCK was mainly expressed in the PVN of the 
hypothalamus. CCK is a hormone peptide both synthesized in the intestine and 
brain. Our result is consistent with a previous report that hypothalamic CCK is 
primarily expressed in PVN, typically in the parvocellular sub-nuclei [144].  
We found that RAMP3 is also mainly expressed in the PVN. RAMP3 is a 
member of RAMP family of single-transmembrane-domain proteins. 
Adrenomedullin receptors and amylin receptors are two well-studied complex 
forms that require RAMP3. Adrenomedullin is a potent endogenous vasodilatory 
peptide [145]. Amylin is a hormone that is co-secreted with insulin from pancreatic 
β cells.  
We further showed that NPY and TNF-α were uniformed expressed in the 
tested regions. AgRP was highly expressed in the VMH. TNF-α is an important 
chemokine involved in systemic inflammation. NPY and ArRP are two important 
player in ARC as orexigenic neurohormones. Our result also detected these two 




detected in other hypothalamic areas using hybridization, but we found that NPY 
mRNA was also expressed in the PVN, VMH and LH, in ascending order of 
expression. AgRP mRNA was also highly expressed in the VMH, consistent with 
the previously reported data [91].  
The distributions of Drd1a and Adra2b showed the similar distribution pattern, 
i.e. mostly expressed in the PVN followed by the VMH and LH. Drd1a plays an 
important role in dopamine pathway. Adra2b has a critical role in regulating 
neurotransmitter release from sympathetic nerves and from adrenergic neurons in 
the CNS. Our result found that both Drd1a and Adra2b were widely expressed in 
the hypothalamus especially in the PVN.  
GH was only expressed in the VMH and LH. GH is synthesized and secreted 
from the pituitary gland. A report showed that GH is also biosynthesized in the LH 
[146]. Our result showed that except PVN, GH can also be synthesized in the VMH 
region.  
Glucocorticoid plays an essential role in the normal physiology, typically 
through hypothalamic-pituitary-adrenal axis. Adipose and hepatic 11β-HSD1 has 
been hotly studied for its possible roles in the obesity development, whereas the 
cerebral 11β-HSD1 is rarely reported. Early report showed that 11β-HSD1 was 




[147]. One group recently investigated the distribution of 11β-HSD1 in the human 
brain, which showed that 11β-HSD1 was also abundantly detected in the human 
hypothalamus [148]. However, the expression pattern of specific neuropeptide can 
vary based on different species [149]. Hypothalamus is the food intake control 
center playing a pivotal role in energy balance. Here we determined where the 
11β-HSD1 mRNA was distributed in the hypothalamic regions using quantitatively 
PCR in the Sprague Dawley rats. Sprague Dawley rats are widely used as a study 
model like Wistar rats. We found that 11β-HSD1 was most expressed in the LH, but 
also abundantly expressed in the other two hypothalamic regions – PVN and VMH. 
This result is consistent with the previous report on Wister rats that 11β-HSD1 was 
highly expressed in the preoptic area and also posterior arcuate nucleus (ARC) (not 
included in the current study) [147]. The previous report failed to clearly detect 
11β-HSD1 expression in other hypothalamic areas. This is probably because the in 
situ hybridization is less sensitive than the quantitative PCR technique. In the 
human study, the 11β-HSD1 was found to be coexpressed with CRH, OXT and 
AVP in the PVN [148]. Similarly, we found 11β-HSD1 was detected in the PVN, 
where CRH, OXT and AVP were highly expressed. This indicates hypothalamic 
11β-HSD1 in the PVN possibly participates in the hypothalamic-pituitary-adrenal 
axis and/or other biological metabolism, e.g. food intake control. Our result clearly 




regions to the same extent in the Sprague Dawley rats. As 11β-HSD1 mRNA is 
mainly expressed in the LH, the 11β-HSD1 may also play an important role in the 
ultra-hypothalamic regions. Further research is needed to validate the physiological 





CHAPTER 3. EFFECTS OF SUGARS ON NEUROPEPTIDES IN DIFFERENT 
HYPOTHALAMIC REGIONS [150] 
Abstract 
It’s been reported that rats with long term additional sugar solutions access gained 
weight. Ample evidence has shown that hypothalamic neuropeptides are pivotal in 
energy homeostasis. In this chapter, we present the results of our studies of the 
effects of various sugars on the expression of hypothalamic neuropeptides. We 
provided Sprague Dawley rats 24 h access to 15% solutions of glucose, fructose, 
sucrose or HFCS and then dissected portions of the paraventricular hypothalamic 
nuclei (PVN), the ventromedial hypothalamus (VMH) and the lateral hypothalamus 
(LH). We then evaluated the expression of several neuropeptides in these tissues, 
all of which were previously shown to be influenced by sugar consumption.  
Rats that had access to sugars consumed less chow. However, although rats fed 
with additional sucrose and HFCS solutions consumed around 10% higher calories 
compared with other groups on average, this differences failed to reach statistically 
significance. In other words, all groups maintained a similar amount of energy 
intake compared with control. 
Of the four sugar solutions tested, only fructose decreased expression of CCK 




TNF-α only in the PVN, not in the VMH or the LH. Fructose and sucrose decreased 
GH in the VMH. Glucose increased Drd1a expression in the PVN only.  
We also found differences of several neuropeptides between different sugar 
groups. Fructose decreased CCK expression compared with glucose. Fructose and 
sucrose decreased GH in both VMH and LH compared with glucose. HFCS 
decreased Drd1a compared with glucose in both PVN and VMH. Both HFCS and 
fructose significantly decreased RAMP3 expression compared with glucose in the 
VMH. By contrast, RAMP3 expression in the LH was significantly reduced in the 
HFCS group when compared to the glucose group. Both fructose and HFCS 
reduced TRH expression when compared with sucrose in the PVN. No differences 
were found for NPY, AgRP, OXT, AVP and Adra2b. 
We conclude that 24 h free access to different sugars can influence the 
expression of several hypothalamic neuropeptides in different ways. Changes in the 
expression of these neuropeptides do not disrupt energy intake immediately but 








It has been known for more than 40 years that long term ad libitum access to sugar 
solutions (glucose, sucrose or fructose) can induce excessive weight gain and 
obesity [45, 151]. Similarly, long term free access to HFCS -55 solutions can also 
induce overweight and obesity [48]. Interestingly, rats adjust their intake of sugar 
solutes from different concentrations [45]. Under normal conditions, energy 
balance is maintained: the body matches energy expenditure and energy intake [51]. 
Long term access to sugar solutions disrupts energy balance so as to induce obesity 
when sugar is freely accessible. The question is: “Which mechanism(s) is(are) 
involved in promoting sugar induced obesity?”  
The system of energy control is composed of both peripheral and central 
regulators. Not all sugars are equally effective in promoting changes in peripheral 
metabolic controls. For example, unlike glucose intake, fructose intake can quickly 
induce hypertriglyceridemia [152], a condition that frequently coexists with obesity, 
type 2 diabetes and metabolic syndrome [153]. Our lab previously reported that 
fructose consumption can quickly suppress the expression of 11β -HSD1 in liver 
and visceral adipose tissues [67] leading to an increase in intracellular levels of 
glucocorticoids [154]. Increased intracellular glucocorticoids are commonly 




are examples of how a nutrient (in this case fructose) can have a dramatic effect on 
gene expression and in that way change short term regulation. 
Sugars can have differing effects on the brain’s food intake control center- the 
hypothalamus, where appetite, motivation and reward processing functions are 
regulated [26]. Different hypothalamic structures and regions influence hunger and 
satiety. For example, Stellar proposed that the VMH and LH acted together to 
control food intake [101]. The “Dual Center Hypothesis” was one of the most 
studied theses in 20th century neurophysiology. The PVN was added to this mix 
later, noting that there were differences in metabolic and behavioral controls of 
hunger [102]. Many neuropeptides synthesized in these hypothalamic regions play 
critical roles in energy maintenance [51].  
We hypothesize that brief access to sugar solutions can change the expression 
pattern of specific hypothalamic neuropeptides that control energy balance. Testing 
this hypothesis is the first step so as to understand whether the change of 
neuropeptides may contribute to the sugar induced obesity. We recently measured 
84 obesity-related genes (using PCR arrays) in the hypothalamus of Sprague 
Dawley rats fed different sugar solutions. We found that several hypothalamic 
neuropeptides are affected differently by different sugars [139]. These 




two important orexigenic neuropeptides - NPY and AgRP in the ARC were not 
changed after sugar treatment. It might be that brief sugar intake somehow bypasses 
ARC and acts on the other hypothalamic regions. As a result, the purpose of the 
present study was to examine how these neuropeptides were affected by different 






Adult male Sprague-Dawley (CD strain) rats (Charles River Laboratories, 
Wilmington, MA) were used. The rats weighed approximately 300 g upon arrival to 
our laboratory. All animals were individually housed. They were maintained on a 
12 h light/dark cycle in a temperature controlled animal room (22± 1 °C). During a 
1 week acclimation period the rats were given free access to water and chow. The 
chow is a nutritionally complete low fat diet [Rodent diet 7012] prepared by Harlan 
Teklad (Bethlehem, PA) containing 3.41 kcal/g of diet, of which 2.14 kcals were 
derived from carbohydrate per gram of chow. All animals were given free access to 
water throughout the experiment. 
Rats were randomly assigned to one of five weight-matched groups (n= 
8/group). One group of rats had ad libitum chow and water and served as the control 
group. Rats assigned to the other groups had ad libitum access to the chow and 
water and to one of four solutions: a 15% weight/volume (w/v) fructose (Tate & 
Lyle, Decatur IL) solution, a 15% (w/v) glucose (Sigma Aldrich, St Louis MO) 
solution, a 15% (total solute per volume) high fructose corn syrup (HFCS) 
(IsoSweet® 5500, 55% fructose–41% glucose, 77% solids, Tate & Lyle, Decatur IL) 




solutions were prepared 24 h in advance and stored at 4 °C until use. The rats were 
maintained with free access to their respective diets for 24 h before sacrifice. This 
method was chosen so as to minimize the stress associated with administering fixed 
volumes of solution intragastrically, as weight gain is thought to be facilitated by 
increased glucocorticoids. All rats were killed by slow replacement of air in a 
specialized chamber with pure CO2 followed by rapid decapitation and 
exsanguination. This method has been approved for use by the Panel on Euthanasia 
of the American Veterinary Medical Association as well as the UM IACUC. All 
procedures described herein are in compliance with the University of Maryland’s 
ACUC guidelines. At the time of sacrifice, the brains were dissected, snap frozen in 
isopentane/dry ice and then stored at -80 °C until use.  
 
Brain sectioning 
 Frozen brains were embedded using M1 embedding matrix (Lipshaw, 
Pittsburgh, PA) on dry ice. An IEC Minot Custom Microtome (Damon/IEC 
Division) was used for cryosectioning. The cryostat’s blade and antiroll plate were 
pretreated with RNaseZap® to remove any possibility of RNase contamination and 
then cleaned with a paper towel soaked in DEPC-treated water. The brain was 




(second edition) at -10°C. Slices were obtained from Interaural 7.70 mm (Bregma 
-1.30 mm) to Interaural 4.48 mm (Bregma -4.52 mm) at a thickness of 110 µm each 
and carefully transferred to pre-cleaned slides (Fisher Scientific, Pittsburgh, PA). 
The slices were then stored at -80 °C until sampled. 
 
Sampling of hypothalamic regions 
RNA is unstable and subject to degradation. When following standard staining 
procedures, brain slices can lose as much as 10% of their initial RNA in as little as 
30 minutes [138]. Water is the key factor that facilitates RNA degradation, however 
RNA integrity can be preserved up to 90 min following ethanol dehydration [138]. 
Preliminary tests showed that cresyl violet staining does not reveal internal 
hypothalamic structures quickly. Rather than attempt to stain the sections in order 
to facilitate accurate dissection we employed a three-step alcohol dehydration 
procedure (specifically 95% alcohol immersion for 30 seconds, followed by 100 % 
alcohol immersion for 1min and then another 100 % alcohol immersion for at least 
an additional minute).  
 After dehydration, the slices were immediately dissected under a light 
microscope. Centered on the third ventricle, several 110 µm slices of each region 




(B-D PrecisionGlide, Franklin Lakes. NJ). Specifically, 6-7 brain slices were used 
for PVN dissection. PVN sampling was initiated approximately at -1.30 mm behind 
Bregma. VMH and LH samples were dissected starting at around -2.12 mm behind 
Bregma. VMH samples were approximately 1.5 mm thick while LH samples were 
approximately 3 mm thick. Captured tissues were carefully transferred into 1.5 ml 
polypropylene eppendorf tubes on ice. 350 µl RLT lysis buffer (containing10 μl β- 
mercaptoethanol per 1 ml Buffer RLT) was added and samples were then subjected 
to 30 sec vortexing for cell breakage and RNA release. Samples were stored at 
-80 °C until RNA extraction.  
 
RNA extraction and cDNA synthesis 
Tissue lysates were thawed in a 37 ℃ water bath until all the salts were dissolved. 
VMH and LH lysates were centrifuged using an Eppendorf centrifuge (model 5424) 
at full speed for 3 min to remove the cell debris. Samples from all three regions 
were then processed using a Qiagen RNeasy micro kit. This kit uses DNase I to 
remove DNA that may affect the downstream applications. RNA quality was 
examined using a NanoDrop 2000 spectrophotometer (A260/A280 >1.8). The 




following the manufacturer’s protocol. The final cDNA products were stored at 
-20 °C until use.  
 
Quantitative real time PCR  
PCR reactions were performed in two replicates using iQ SYBR Green Supermix 
and a Bio-Rad CFX96 Bio-Rad system. The program used for all PCR reactions 
was 95°C for 3 min and 40 cycles of 95°C for 15 sec, annealing temperature (Ta) 
for 30 sec (see Table 1) and 68°C for 30 sec. A melt curve analysis was then 
appended. All primers that were designed using Beacon Designer 7 software met 
the ΔΔCt requirement for the product length less than 200 bp. 
Data analysis 
The formula below was used to plot the final result from qPCR data:  
𝛥𝛥𝛥𝛥𝛥𝛥(𝛥𝛥𝑡𝑡𝑡𝑡𝛥𝛥) = 𝛥𝛥𝛥𝛥(𝛥𝛥𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝛥𝛥, 𝛥𝛥𝑡𝑡𝑡𝑡𝛥𝛥) − 𝛥𝛥𝛥𝛥(𝑡𝑡𝑡𝑡𝑟𝑟, 𝛥𝛥𝑡𝑡𝑡𝑡𝛥𝛥)       
𝛥𝛥𝛥𝛥𝛥𝛥(𝑐𝑐𝑡𝑡𝑐𝑐𝑐𝑐𝑐𝑐𝑡𝑡𝑡𝑡𝛥𝛥𝑐𝑐𝑡𝑡) = 𝛥𝛥𝛥𝛥(𝛥𝛥𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝛥𝛥, 𝑐𝑐𝑡𝑡𝑐𝑐𝑐𝑐𝑐𝑐𝑡𝑡𝑡𝑡𝛥𝛥𝑐𝑐𝑡𝑡) − 𝛥𝛥𝛥𝛥(𝑡𝑡𝑡𝑡𝑟𝑟, 𝑐𝑐𝑡𝑡𝑐𝑐𝑐𝑐𝑐𝑐𝑡𝑡𝑡𝑡𝛥𝛥𝑐𝑐𝑡𝑡) 
2−𝛥𝛥𝛥𝛥𝛥𝛥𝑡𝑡 = 2𝛥𝛥𝛥𝛥𝑡𝑡( 𝑐𝑐𝑀𝑀𝑐𝑐𝐻𝐻𝑐𝑐𝑐𝑐𝑀𝑀𝑡𝑡𝑐𝑐𝑐𝑐)−𝛥𝛥𝛥𝛥𝑡𝑡(𝑡𝑡𝐻𝐻𝑀𝑀𝑡𝑡) 
The Ct mean value from RPLP1 was used as the reference gene as before [139] 




expressed as means ± SEM. One way ANOVA with Duncan post hoc testing was 
applied to food intake and energy intake using IBM SPSS Statistics 21. Data were 
pre-screened using Dixon's Q test. Student’s t test option was applied to the 2−𝛥𝛥𝛥𝛥𝑡𝑡 
values to determine significance between groups using JMP Pro 10.0.2. Pearson’s 
correlation coefficients were calculated to evaluate the relationship between sugar 
intake and the expression of the neuropeptides. P values less than 0.05 were 






Table 6 Primer sets for chapter 3 
  




RPLP1 sense GAAGAATCCGAGGATGACA 81 51 
RPLP1 antisense CAGGTTCAGCTCTTTATTGG 
CCK sense GCGTTTATTTATTAAGTCC 133 43 
CCK antisense ATAGCATAGCAACATTAG 
Tnf-α sense CCAATCTGTGTCCTTCTAA 85 47 
Tnf-α antisense TTCTGAGCATCGTAGTTG 
RAMP3 sense CAAGGTCATCTGGAAGGT 109 50 
 RAMP3 antisense GACTCCTAACAACTCCATTC 
GH sense GTCTGTTTGCCAATGCTGTG 152 55 





TRH antisense GGGGTGCTGTCGTTTGTG 
CRH sense TGGAGATTATCGGGAAAT 158 47 





Food and energy intake 
When sugars were presented, the chow intake in all sugar fed groups decreased 
significantly compared with the control group. However, the average total caloric 
intakes of each group over the 24 h experimental period were maintained, and did 
not differ from one another. The percentage of total calories derived from sugar 
intake ranged from 44 to 53%. Rats fed fructose consumed significantly less sugar 
than rats fed sucrose. No other statistically significant differences between 





Table 7 Calorie intake of rats fed with different sugars 
Group Water Glucose Sucrose HFCS Fructose 
Chow Intake (g) 28.8±3.3a 14.1±1.6b 15.2±2.3b 17.5±2.7b 17.6±3.7b 
Sugar Intake (g) NA 11.5±0.6ab 13.2±1.0a 11.1±0.9ab 9.7±1.4b 
Chow Calorie (Kcal) 93.1±10.8a 46.2±5.2b 49.56±7.4b 57.18±8.7b 57.67±12.7b 
Sugar Calorie (Kcal) NA 46.2±2.2ab 52.71±3.9a 44.6±3.4ab 38.8±5.7b 
Total Calorie (Kcal) 93.1±10.8a 92.3±4.8a 102.3±7.8a 101.8±7.0a 96.4±15.2a 
% calories intake as 
sugar  
NA 51.1±4.3 52.8±4.9 45.9±5.6 44.3±5.2 







Neuropeptides regulated by sugars 
CCK 
Fructose downregulated CCK expression in the PVN (p<0.05). (Refer to Figure 
11A). CCK expression was not changed in the VMH or in the LH (refer to Figure 
11B and C). No other differences were statistically significant.  
TNF-α 
Glucose and sucrose intake significantly increased the expression of TNF-α in the 
PVN. HFCS and fructose groups failed to change TNF-α in the PVN (Refer to 
Figure 11D). No other differences between groups were found in the VMH or LH 
(Refer to Figure 11E and F). 
GH 
We failed to detect any GH in the PVN. In the VMH, sucrose and fructose 
decreased GH expression. Compared with glucose solution, the other three sugars 
decreased GH expression (Refer to Figure 11G). In the LH, only sucrose and 
fructose decreased GH expression compared with glucose solution (Refer to Figure 
11H). Compared with glucose, both sucrose and fructose decreased its expression 





We found that glucose increased expression of hypothalamic Drd1a in the PVN 
only. Compared with glucose, HFCS decreased its expression in both PVN and 




Figure 11 Different sugars affect the expression of CCK, TNF-α, GH and 
Drd1a in the PVN, VMH and LH.  
(A-C) Expression of CCK mRNA in different groups was expressed in the PVN, 
VMH and LH. Of the four sugar solutions tested, only fructose decreased 
expression of CCK significantly only in the PVN. (D-F) Expression of TNF-α 
mRNA in different sugar groups was expressed in the PVN, VMH and LH. Glucose 
and sucrose significantly increased the expression of TNF-α only in the PVN, not in 
the VMH or the LH (G-H) Expression of GH mRNA in different sugar groups was 
observed in the VMH and LH. Fructose and sucrose decreased GH in the VMH. 
Compared with glucose, sucrose, HFCS and fructose decreased GH significantly in 
the VMH and sucrose and fructose decreased GH significantly in the LH. (I-K) 
Expression of Drd1a mRNA in different sugar groups was observed in the PVN, 
VMH and LH. Glucose increased Drd1a expression in the PVN only. Compared 
with the glucose, HFCS decreased Drd1a expression in the PVN and VMH.  
All values on Y axis were expressed as 2-ΔCt 












RAMP3, TRH and 11βHSD1 
When compared to controls, none of the sugars tested had a significant effect on 
RAMP3, TRH or CRH messages (Refer to Figure 12). However, some differences 
in RAMP3 and TRH between sugar groups were found. Both HFCS and fructose 
significantly decreased RAMP3 expression compared with glucose in the VMH 
(Refer to Figure 12B). By contrast, in the LH RAMP3 expression was significantly 
reduced in the HFCS group when compared to the glucose group (Refer to Figure 
12C). Both fructose and HFCS reduced TRH expression when compared with 
sucrose in the PVN (Refer to Figure 12D).  No other differences were found in the 






Figure 12  Different sugars affect the expression of RAMP3, TRH and 
11βHSD1 in the PVN, VMH and LH.  
(A-C) Expression of RAMP3 mRNA in different groups was expressed in PVN, 
VMH and LH. Both HFCS and fructose significantly decreased RAMP3 expression 
compared with glucose in the VMH. By contrast, RAMP3 expression in the LH was 
significantly reduced in the HFCS group when compared to the glucose group. (D-F) 
Expression of TRH mRNA in different sugar groups was observed in PVN, VMH 
and LH. Both fructose and HFCS reduced TRH expression when compared with 
sucrose in the PVN. (G-I) Expression of 11βHSD1 mRNA in different sugar groups 
was observed in PVN, VMH and LH. Sugars did not significantly change 
11β-HSD1 mRNA expression in VMH compared with water group. HFCS 
significantly increased 11β-HSD1 mRNA expression in the VMH compared with 
glucose or sucrose. 
All values on Y axis were expressed as 2-ΔCt 













Several neuropeptides that were not affected by sugar intake 
The other neuropeptides tested that were not significantly affected by sugar intake 





Figure 13 Hypothalamic neuropeptides that were not affected by 24 hour 
exposure to sugar solutions.  
(A-R) expression of CRH, NPY, AgRP, Adra2b, OXT and AVP in different sugar 
groups in PVN, VMH and LH. All sugars failed significantly change the mRNA 
expression of these neuropeptides in PVN, VMH or LH. 














Correlation between fructose/glucose intake and neuropeptide expression 
Pearson correlation analyses revealed that CCK expression was regulated by 
fructose but not by glucose. A statistically significant inverse correlation between 
CCK expression in the PVN and fructose intake (r= -0.36, p<0.05) was found (refer 
to Figure 14A-B). No correlations between fructose or glucose intake and TNF-α 
were statistically significant (refer to Figure 14C-D). GH expression is inversely 
correlated with fructose intake (r=-0.44, p=0.01) and positively correlated with 
glucose intake (r=0.59, p=0.00) (refer to Figure 14E-F). The correlations between 
fructose or glucose intakes with other neuropeptides in any of the three 




Figure 14 Effect of fructose or glucose on the expression of several 
neuropeptides.  
Expression of CCK in the PVN is negatively correlated with fructose intake. (B) 
CCK expression in the PVN is not significantly correlated with glucose intake. (C) 
Expression of TNF-α in the PVN is not correlated with fructose intake. (D) TNF-α 
expression in the PVN is not significantly correlated with glucose intake. (E) 
Expression of GH in the VMH is negatively correlated with fructose intake. (F) GH 
expression in the VMH is significantly correlated with glucose intake. 
Values on Y axis were expressed as 2-ΔCt, and values on X axis were express as 




















Sugar induced obesity is well documented, whereas the mechanisms behind it are 
still not clear. Differences in sugar metabolism in the liver are not sufficient to 
explain how long term ad libitum sugar access can cause weight gain and/or even 
obesity. We hypothesize that sugars can affect the expression pattern of 
hypothalamic neuropeptides that may bias energy balance in the long term. To test 
the initial response of the rats, we gave the rats a brief exposure of different sugar 
solutions. Our results showed that under ad libitum conditions, fructose intakes 
were comparable (or even a little lower(see also [106])) to intakes of other sugars. 
This ad libitum method more closely mimics conditions that in humans lead to 
excess intake and obesity. It should be noted that some popular sweetened drinks 
may have over 12% sugar content[38] and some juices even have higher sugar 
content[39]. 
Free access to glucose, fructose, sucrose or HFCS can lead to excessive weight 
gain and/or obesity in the Sprague Dawley rat [45, 48, 151]. We found evidence 
that brief exposure to different sugars can change the expression of CCK and 
TNF-α in the PVN as well as GH in the VMH. The responses to sugars are not the 
result from excess energy intake, as total caloric intake did not differ among all five 




CCK is well known as an effective hunger suppressant [157]. Brain CCK 
receptor deficiency results in hyperphagia and decreased responsiveness to high fat 
diet in rats [158-160]. Dorsal medial hypothalamic CCK inhibits food intake for at 
least 22 h [161, 162]. CCK microinfused in the PVN inhibits gastric emptying and 
stimulates colonic transit in a dose dependent way [163]. It has been reported that 
CCK synthesis in the hypothalamus is disrupted during diabetes development [144]. 
CCK release from PVN in response to a gavaged meal is also compromised in the 
obese (fa/fa) Zucker rats [164]. These observations support the view that 
hypothalamic CCK plays an important role in energy control. We recently reported 
that 24 hour access to glucose solution upregulates CCK expression whereas access 
to fructose results in significant downregulation of CCK [139]. In the current study, 
we found that fructose affects the hypothalamus by down-regulating CCK mainly 
in the PVN, not in the VMH or the LH. It has been previously reported that 
hypothalamic CCK is primarily expressed in PVN, typically in the parvocellular 
sub-nuclei [144]. This may suggest that effect of sugars on CCK is confined to the 
PVN region. CCK expression is not significantly different in response to sucrose or 
HFCS.  
TNF-α is an important chemokine involved in systemic inflammation. High 




proportional to the decrease of both food and water intake [165]. It needs to be 
noted that the effect of TNF-α on food intake is mild compared with the effects of 
either insulin or leptin[166]. On the contrary, hypothalamic pro-inflammatory 
signaling can lead to impaired insulin sensitivity [167], increasing the potential for 
excess weight gain [168]. In the current study we found glucose and sucrose 
increased TNF-α. This effect is similar to that caused by high fat diet[169]. By 
contrast HFCS and fructose had no significant effect on TNF-α expression. The 
slight increase of TNF-α caused by glucose or sucrose was probably insufficient to 
have an effect on energy balance in the short term. Although fructose was reported 
to increase TNF-α in the whole hypothalamus[139], that observation is probably a 
reflection of the fact that the entire hypothalamus was sampled.  
GH is known to be a peptide that contributes to the energy expenditure and 
lipid oxidation[170]. GH is critical for fat mobilization during fasting or starvation 
state when insulin is suppressed[171, 172]. Adults with GH deficiency usually have 
increased body fat mass and decreased extracellular fluid volume[173]. We 
recently reported that GH expression was upregulated by glucose intake, in the 
current study we further found fructose decreased GH expression in specific 
hypothalamic areas[139]. Although the effect of glucose intake on the GH 




GH expression and glucose intake is robust (P<0.05). Because fructose can induce 
hypertriglyceridemia, our observation is also consistent with the fact that plasma 
triglycerides inhibit GH release[174].  
Drd1a is a receptor for dopamine. Dopamine signalling is proposed as part of 
the mechanism of the overeating[175]. Activation of Drd1a expressing neurons in 
the medial prefrontal cortex (mPFC) can increase feeding[176]. Activation of 
amygdala D2 receptor can reduce food intake and operant behavior for sucrose in 
Male Sprague Dawley rats, whereas Drd1a stimulation or blockade cannot[177]. 
High level of D1 receptor expression in the VMH may contribute to the specific 
feeding pattern in obese rats[178]. Interestingly, we found that glucose can increase 
the expression of Drd1a in the PVN. HFCS had opposite effect on Drd1a expression 
in PVN and VMH. 
RAMP3 can interact with several protein-coupled receptors. Adrenomedullin 
receptors and amylin receptors are two well-studied complex forms that require 
RAMP3. Adrenomedullin is a potent endogenous vasodilatory peptide. Amylin is 
secreted in the gut in response to nutrient intake and suppresses glucagon secretion. 
It also slows gastric emptying and delays glucose entering into the circulation. Its 
agonist can be used for type 2 diabetic patients to control postprandial glucose 




adiposity [180]. Unlike CCK, glucose and fructose failed to affect the expression of 
RAMP3 in the PVN. Interestingly, although RAMP3 is mainly expressed in PVN, 
HFCS suppressed RAMP3 in both the VMH and the LH when compared to the 
glucose group, but not with the water-fed control group. 
Adipose tissue 11β-HSD1 has been studied for its possible roles in obesity 
development [78-80], whereas the brain 11β-HSD1 is rarely reported. We found 
11β-HSD1 was detected in the PVN, where CRH, OXT and AVP were highly 
expressed. Our observations make it plausible that hypothalamic 11β-HSD1 in the 
PVN participates in the hypothalamic-pituitary-adrenal axis and/or other biological 
metabolism, e.g. food intake control. Central glucocorticoids play an important role 
in energy homeostasis [181, 182]. Intraventricular glucocorticoid injection 
increases the body weight gain in adrenalectomized rats [182] and 11β-HSD1 
deficiency increases glycolysis and energy substrate (lactate) in the brain [183], 
indicating that hypothalamic 11β-HSD1 may play a critical role in the control of 
energy homeostasis. We have previously shown that sugars can affect the 
expression of several neuropeptides in the hypothalamus. Here we further showed 
that sugars also increased the hypothalamic expression of 11β-HSD1 in both PVN 
and VMH. Interestingly, when we combined the PVN, VMH and LH data together, 




sugars on the hypothalamic glucocorticoids is probably mainly in the PVN and 
VMH areas.  
Finally, TRH is mainly located in the PVN and its secretion is connected with 
pituitary hormone release. TRH has an anorexigenic effect both by central or 
peripheral administration [111]. Differently from the results from the whole 
hypothalamus reported earlier [139], fructose failed to significantly decrease TRH 
in the PVN, the VMH or the LH. It has been pointed out elsewhere [184] that TRH 
expression is highly specific to the PVN. We failed to replicate the previously 
reported finding (that fructose promoted decreases in TRH message and that HFCS 
intake downregulated CRH message). It is likely that this difference in observation 
is attributable to the differences in dissection/sampling. Earlier work from our 
laboratory used tissue from a much larger region of the hypothalamus, whereas the 
sampling performed in this paper was confined to discreet hypothalamic nuclei or 
regions. 
When we examined food intake and energy intake, we found that standard 
chow consumption was reduced but total energy intake remained unchanged. 
Although the reduction of CCK and GH or increase of TNF-α failed to affect 
energy intake immediately, the expression change of these neuropeptides could 




We have compared the effects of HFCS to the effects of other sugars including 
glucose, sucrose and fructose. Sucrose and HFCS have differing effects on several 
neuropeptides including TNF-α, GH, RAMP3 and TRH. Fructose intake, when 
unaccompanied by comparable glucose intake, can lead to malabsorption[41]. As a 
result HFCS (55% fructose, 41% glucose) has the potential to result in greater 
malabsorption than does sucrose. Different sugars may also have different effects 




We have presented evidence here that makes it clear that different sugars can and do 
have different effects on different targets, even within the hypothalamus. Our study 
clearly indicated that brief sugar intake can change hypothalamic neuropeptides. 
We found a close link between the expression of the neuropeptide CCK and GH and 
fructose intake. No differences in CCK or GH between HFCS and sucrose groups 
were observed. The mRNA measurements in the current study do not predict 
protein levels but reflects on the expression changes of the neuropeptides which are 




whether the change of these neuropeptides is sufficient for inducing obesity 




CHAPTER 4. SUGARS AND ADIPOSITY HORMONES 
Abstract 
Several neuroendocrine systems are important for energy balance. We have shown 
evidence that different sugars can affect expression of different neuropeptides. In 
this chapter, we will focus on the effects of sugars on the important circulating 
regulator adiposity hormones insulin and leptin. We recently reported that fructose 
can quickly increase circulating triglycerides but insulin was not affected. We then 
measured the other adiposity hormone leptin in the sera of Sprague Dawley rats fed 
with different 15% sugar solutions for 24 hour. Surprisingly, sugars slightly 
increased leptin level on average but failed to reach significant level. However, 
literature research showed that long term use of sugars can lead to the disorder of 
insulin and leptin signaling pathways. Therefore, we believe that sugar is not the 
direct factor that affects these adiposity hormones. However, sugar induced obesity 
with accumulated body fat mass will finally generate more leptin accompanied with 
increased insulin secretion.  
Introduction 
Fructose that accounts for much of the increase in sugar intake in the American diet 
has a potential role in contributing to the current obesity problem [2]. Unlike 




condition that frequently coexists with obesity, type 2 diabetes and metabolic 
syndrome [153]. Our lab previously reported that fructose consumption can quickly 
suppress the expression of 11β -HSD1 in liver and visceral adipose tissues [62] 
leading to an increase in intracellular levels of glucocorticoids [154]. Increased 
intracellular glucocorticoids are commonly observed in obesity in human and 
animal models [155, 156]. 
To evaluate the effects of sugars on obesity development, we have also 
measured two hormones known to participate in the control of intake: insulin and 
leptin. To date, only insulin and leptin meet all the criteria of adiposity hormones: 1) 
they circulate at levels proportional to body fat content, which further determines 
the amount they enter the CNS. 2) their receptors are expressed by brain neurons 
involved in energy intake, specifically high level of both hormones in the brain 
reduces food intake, whereas deficiency of either hormone has the opposite effect 
[185, 186].  
Insulin is an important adiposity hormone which is secreted from β cells of the 
pancreas. Deficiency of insulin can lead to an increase in NPY expression and 
intracerebroventricular insulin infusion can reduce diabetic hyperphagia [187]. 




obesity with increases in body fat composition [188]. However, we previously 
showed that sugars failed to affect insulin after 24 hour exposure.  
Similarly, leptin knockout mice become obese. Leptin can inhibit NPY gene 
expression [189] and activate POMC/CART neurons located in ARC. Loss of NPY 
can even attenuates the obesity syndrome of ob/ob mice [97]. Although leptin 
activates POMC via PI3K signaling pathway, PI3K inhibition only cannot induce 
obesity in a long term [190]. Therefore, POMC is probably not the only target of 
leptin to control food intake. Exogenous leptin infusion can prevent the diabetic 
hyperphagia in a rat model of insulin deficient diabetes [191]. How sugars can 
affect another adiposity - leptin in short term is unknown. In the current project, we 
measured leptin levels in rats fed with different sugars and then we will deeply 
discuss how sugars affect the adiposity hormones as well as other peripheral 
regulators.  
Materials and Methods 
Animal treatment 
Adult male Sprague-Dawley (CD strain) rats (Charles River Laboratories, 
Wilmington, MA) weighted approximately 300 g were used. Upon arrival, all 
animals were individually housed and maintained on a 12 h light/dark cycle at room 




free access to the water and chow. The chow is a nutritionally complete low fat diet 
[Rodent diet 7012] prepared by Harlan Teklad (Bethlehem, PA) containing 3.41 
kcal/g of diet of which 2.14 kcal were derived from carbohydrate per gram of chow. 
All animals were given free access to water throughout the experiment. 
Rats were randomly assigned to one of five weight-matched groups (n= 
8/group). One group of rats had ad libitum chow and water and served as the control 
group. Rats assigned to the other groups had ad libitum access to the chow and 
water and to one of the four solutions: the 15%weight/volume (w/v) fructose (Tate 
& Lyle, Decatur IL) solution, the 15% (w/v) glucose (Sigma Aldrich, St Louis MO) 
solution, the 15% (w/v) high fructose corn syrup (HFCS) (IsoSweet® 5500, 55 % 
fructose–41 % glucose, 77 % solids, Tate & Lyle, Decatur IL) or the 15%(w/v) 
sucrose (Domino Foods, Baltimore MD) solution. All sugar solutions were 
prepared 24 h in advance and stored at 4 °C until use. The rats were maintained on 
their respective diets for 24 h before sacrifice. All rats were killed by slow 
replacement of air in a specialized chamber with pure CO2 followed by rapid 
decapitation and exsanguination. This method has been approved for use by the 
Panel on Euthanasia of the American Veterinary Medical Association as well as the 
UM IACUC. All procedures described herein are in compliance with the University 




Plasma Leptin Measures 
Leptin concentrations were determined using the EZRL-83K, Rat Leptin ELISA kit 
(EMD Millipore) from sera of Sprague Dawley rats fed with different sugar 
solutions.  
Statistics 
One way ANOVA with Duncan post hoc testing was applied to the 2-ΔCt values 
using IBM SPSS Statistics 21. P values of less than 0.05 were considered 
statistically significant. 
Results 






Figure 15 Plasma leptin level of rats fed with different sugars.  
Leptin were determined using EZRL-83K, Rat Leptin ELISA kit (EMD Millipore) 
from sera of Sprague Dawley rats. These rats were fed with different sugar 
solutions including water, 15% glucose, 15% sucrose, 15% HFCS and 15% 
fructose. On average, all sugars slightly increased leptin level, but this change failed 















Glucose sweetened drinks are more effective than fructose sweetened drinks in 
their ability to increase insulin in humans within one hour [26]. This effect 
disappears quickly, as evidenced that 24 hour sugar exposure failed to change 
insulin level in in Sprague Dawley rats [63, 70]. Rats initiate more meals/day 
(approximately 12 meals/day) than do humans[192], so glucose-induced increases 
in insulin should be higher than that caused by fructose intake. Although insulin can 
inhibit food intake, it is also required for adiposity. Hyperphagia with low levels of 
insulin fails to promote obesity. High insulin levels in the long term can drive 
obesity in a brain insulin independent pathway[193]. As a result, long term frequent 
use of glucose may also induce obesity.  
One important obesity associated disorder is type 2 diabetes featured with 
insulin resistance. Fructose enriched diets or solutions can induce hyperinsulinemia 
after two weeks treatment [106, 194, 195]. This is an early signal of insulin 
resistance. Indeed, even moderate amounts of fructose or sucrose can alter hepatic 
insulin sensitivity and lipid metabolism compared with glucose [196]. Human 




hepatic and/or muscle/adipose tissue insulin resistance [197, 198]. Long term use of 
fructose, e.g. in the form of sucrose form can cause insulin insensibility [199].  
Fructose and glucose share several of the same metabolic pathways. The main 
reason that fructose can cause insulin resistance is probably due to the unique 
metabolism of fructose in the liver. Fructose is mainly metabolized in the liver and 
quickly stimulates an increase in fasting and postprandial triglycerides. This is not 
only because of hepatic de novo lipogenesis but also due to the increased 
VLDL-triglyceride secretion as well as a decreased VLDL-triglyceride clearance. 
A case report showed that hypertriglyceridemia may not be an obligatory cause for 
insulin resistance or vice versa [200].  
In addition to insulin resistance, fructose can also induce glucose intolerance. 
Glucose intolerance is a pre-diabetic state of hyperglycemia. It is often associated 
with insulin resistance. A high-fructose diet can cause hyperinsulinemia, while a 
high-fat diet can result in impaired pancreatic function of insulin secretion. Both of 
them can induce glucose intolerance [201]. This is partly due to impaired 
suppression of hepatic glucose output as well as fructose induced gluconeogenesis 





Neither glucose nor fructose sweetened solutions affect circulating leptin in 
humans within one hour [26]. We also failed to detect significant change of plasma 
leptin in 24 hour sugar-treated rats. However, glucose enriched diet (60% by 
calorie), but not fructose enriched diet, increases circulating leptin of 5 hour fasted 
Sprague Dawley rats after two weeks treatment [194]. Similarly, glucose, sucrose 
and fructose solutions increased fasting leptin after two weeks [106]. Sugar 
solutions may cause leptin resistance that can further accelerates diet induced 
obesity [202]. Obesity with leptin resistance has been repeatedly reported. In 
addition to the defect of leptin receptors [203], other factors that can induce leptin 
resistance include: brown adipose tissue removal [204], unknown factors from 
obesity independent of melanocortin-4 (MC4) receptors [205], melanocortin 
receptor blockade associated with mutation of Ay gene [206]. Dysfunction of leptin 
transport may lead to leptin resistance and obesity evidenced by the obese humans 
with low leptin levels in cerebrospinal fluid [207]. The expression of the 
suppressors-of-cytokine-signaling (SOCS) 3 is another mechanism that can 
contribute to leptin resistance [208]. The mechanism of how sugars can induce 
leptin resistance is not quite clear yet, but understanding this is undoubtedly crucial 




CHAPTER 5. SUMMARY AND PROSPECT 
Time course of the sugar study 
Obesity is a complicated disease that can be induced in many ways. Diet induced 
obesity is one of the most widely used models, as this closely mimics the obesity 
and/or associated metabolic diseases emerging in the world. High fat, high sugar or 
both can generate diet-induced obesity. With the increasing interest in the sugar 
hypothesis, typically HFCS, in the current obesity epidemic in US, our lab designed 
several experiments to investigate the effect of brief sugar intake on the energy 
control of Sprague Dawley rats. Below is a list of previous findings from our lab 
about sugar induced obesity. 
 11β-HSD-1, that interconverts active and inactive glucocorticoid, is frequently 
confirmed to be closely related with obesity, typically central obesity. For example, 
11β-HSD-1 in liver and adipose is deregulated in both human and animal models of 
obesity. Between the years 2006 to 2009, our lab found that ten weeks’ exposure to 
sucrose solution increased both the body fat, fasting insulin and the 11β-HSD-1 
mRNA in adipose tissues. Fructose solutions can effectively increase 11βHSD1 
message in mesenteric adipose and liver just within 24 hours. This result clearly 
explained why fructose is more effective to increase visceral fats than glucose. 




after one week treatment. Additionally, our lab observed that fructose can also 
quickly increase plasma triglycerides which is a well-known risk factor for obesity 
and metabolic diseases. The sugars including sucrose, fructose and glucose have 
their distinct metabolic and endocrine responses, of which fructose can uniquely 
induce glucocorticoid dysregulation in liver and adipose within 24 hour. 
 Because of the high efficiency of fructose induced hypertriglyceridemia as well 
as increased 11βHSD1 expression, our lab continued using this model to further 
study the effects of initial sugar intake on the brain, typically, the hypothalamus. 
The hypothalamus is considered as the control center for food/caloric intake with 
complicated neuronal signaling network. Between the years 2010 to 2012, our lab 
briefly treated Sprague Dawley rats with different sugar solutions for 24 hours. In 
addition to glucose, sucrose and fructose, HFCS was also included since it was 
increasingly used in the food market today. As expected, our lab repeated the 
previous finding that fructose containing sugars can quickly cause 
hypertriglyceridemia. However, circulating insulin as well as glucose were not 
significantly changed. This is not surprising, since it normally takes months for free 
access to sugar solutions to cause significant body weight gain in rodent animals. 
The sugar increased insulin is probably the consequence of increased body fat 




related genes in the hypothalamus. Those genes that were found be significantly 
changed by sugars were re-examined by individual PCR assays. Several 
hypothalamic neuropeptides that were found to be changed by sugar intake 
included CCK, TNF-α, RMAP3, CRH, TRH and GH. Interestingly, the 
well-studied neuropeptides in the ARC like NPY were not affected.  
 However, the hypothalamus is composed of different functional regions, each 
of which have their district functions in food/caloric intake. For example, ablation 
of PVN or VMH can cause hyperphagia and obesity whereas ablation of LH will do 
the opposite. This stimulated the idea of the current project to further examine these 
neuropeptides in specific hypothalamic regions.  
  
Summary of the current study 
There are many neuropeptides that are associated with energy balance. Thanks to 
the preliminary PCR array experiment, we only focused on those neuropeptides that 
were indicated to be affected by sugar access. These neuropeptides usually have 
their distinct distributions. For example, CCK, RAMP3, TRH, CRH are mainly 
expressed in the PVN whereas GH are mainly synthesized in the VMH and LH. 




hypothalamus. We early expected that the effects of sugars on these neuropeptides 
should be mainly restricted to the regions that mainly biosynthesized them. 
In the current dissertation, we showed evidence that brief sugar intake affected 
expression of several hypothalamic neuropeptides. Specifically, sugars containing 
fructose can repress the expression of anorexic neuropeptide CCK in the PVN, and 
GH in the VMH which may facilitate fat burning. Sucrose and glucose can both 
increase the TNF-α expression in the PVN, a chemokine involved in inflammation 
and may impair insulin signaling to cause obesity. Additionally, glucose solutions 
also quickly increased Drd1a expression, which might amply dopamine activity and 
increase the risk of overeating and excess energy intake. Although we failed to 
detect significant change of the other neuropeptides, we believe our result is 
convincing since we measured these neuropeptides within specific hypothalamic 
regions that were accurately dissected compared with the whole hypothalamus.  
This experimental design is an important and also necessary step for us to 
understand how sugars affect the energy control in the long term. It’s too early to 
give a conclusive assertion about sugar induced obesity. Based on what have so far, 
we attempt to propose that sugars can cause energy imbalance via both peripheral 
and hypothalamic signals including increased circulating triglycerides, increased 




[Figure 16]. The final consequence is the increased body fat as well as adiposity 
hormones. All of these can contribute to obesity, type II diabetes and metabolic 
syndrome.   
 
 
Figure 16 Sugar induced energy imbalance.  
The dietary sugars can reach the neural circuitry in specific brain areas including 
hypothalamus and NTS via both the circulation system as well as the vagus nerve 
system. As a consequence, the disrupted energy homeostasis leads to body weight 






Sucrose and HFCS are two of the most widely used sweeteners in the US market. 
As both of them have the ability of inducing obesity, the argument focusing on the 
HFCS or fructose itself is a little bit “off-target”. Although fat also can also induce 
obesity, it is excluded as the main cause of the current obesity epidemic because 
years of promotion of low fat or fat free products has failed to slow down the 
obesity increasing rate. HFCS use has dropped in recent years. This decrease hasn’t 
significantly affected the increasing obesity rate either. It’s not known whether 
there is a lagged effect caused by long-term use of sugars. Perhaps there is a 
threshold for sugar use to cause obesity? The promotion of low sugar or sugar free 
products in the future is a good strategy to examine whether sugars or other factors 
involved contribute to the current obesity epidemic. It really makes things more 
complicated when some people argue about whether animal models are capable of 
mimicking human behaviors. We have used rodent models to do multiple studies 
and found a close similarity in both physiology and response to many diet stimuli.  
 We admit that there are limitations for the current study, for example, whether 
change of hypothalamic CCK expression is sufficient to explain part of fructose 




can be done based on the current results. Below is a brief proposal for the 
downstream study.  
Title: Investigation of the role of hypothalamic CCK in the fructose induced 
obesity. 
Hypothesis: hypothalamic CCK plays a central role in fructose induced obesity. 
Rationale: 
1. CCK is an anorexic neuropeptide. For example, inactivation of the brain CCK 
receptors results in hyperphagia whereas increased hypothalamic CCK inhibits 
food intake, increase gastric emptying and stimulate bowel movement. On the 
other hand, the hypothalamic CCK pathway is disrupted in both diabetic and 
obese rats.  
2. Fructose can effectively reduce hypothalamic CCK expression. This is both 
found in the PVN as well as the whole hypothalamus.  
Objective 1: to understand the relationship between the hypothalamic CCK and the 
obesity 
Experiment 1: we can measure CCK levels in PVN in both fed and fasted state of 
rats as well as in lean vs obese rats. Manipulation of CCK level in the hypothalamus 




and fasted state can further find out whether CCK expression in the PVN is a 
regulator during the fasted/fed states. Moreover, if CCK is closely related with 
obesity, then the CCK expression will be probably different between obese and lean 
rats. 
Objective 2: to confirm how effective of hypothalamic CCK can promote obesity 
and/or its associative metabolic change.  
Experiment 2: we can modulate CCK level in rats by downregulating CCK in the 
PVN using siRNA/knockout techniques and measure several metabolic parameters 
in rats. Previous research did show that CCK is an anorexic neuropeptide, but how 
effective CCK can cause obesity is still not quite understood. The siRNA or 
conditional knockout technique is undoubtedly is a powerful tool to evaluate the 
effect of CCK repression on the obesity development. After knockdown or 
knockout, several metabolic parameters can be recorded. These include body 
weight, lipid profile, and adiposity hormone as well as insulin sensitivity and so on.   
Objective 3: To find out the relationship between long term access to fructose 
solution and CCK expression.  
Experiment 3: as is known, free access to fructose solutions can cause significant 
body weight gain after several months’ treatment. The current study only lasted for 




To evaluate whether CCK expression is closed related with fructose induced 
obesity. CCK level in the PVN should be monitored during the whole process to 
fructose treatment until body weight changes significantly.  
Objective 4: to investigate whether CCK manipulation can stop or reverse fructose 
induced obesity. 
Experiment 4: if CCK is the main contributor to the fructose induced obesity. CCK 
overexpression should significantly ameliorate fructose induced obesity. During 
this experiment we can use hypothalamic CCK overexpressed rats as experimental 
group to examine whether fructose induced obesity as well as metabolic syndrome 
can be modified in the CCK genetic modified rats. Another way to do this is to 
inject CCK to the PVN of obese rats fed with fructose on a regular manner. This is 
to further examine whether CCK can reverse fructose induced obesity.  
 The above is just a brief example for the possible future work following the 
current project. Further work can also be done for protein measurement, varying 
fructose/glucose ratio, effect of sugars on the other areas of the brain, vagotomy 
studies and so on. We believe the sugar induced obesity is complicated and may 
involve many pathways. More work should be done to address these questions, 






1. Obesity: a medical condition in which excess body fat has accumulated to 
the extent that it may have a negative effect on health, leading to reduced life 
expectancy and/or increased health problems. (Wikipedia) 
2. Energy homeostasis: The biological process by which the body maintains 
body fat stores by balancing energy intake with energy expenditure over time. 
[52] 
3. Insulin resistance: a physiological condition in which cells fail to respond to 
the normal actions of the hormone insulin. (Wikipedia)  
4. Leptin resistance: the failure of endogenous or exogenous leptin to promote 
anticipated salutary metabolic outcomes in states of over-nutrition or obesity, 
although the hormone's inability to promote desired responses in specific 
situations results from multiple molecular, neural, behavioral, and 
environmental mechanisms. [209] A state in which the body is no longer 
responsive to the anorexic effect of exogenous leptin. [52] 
5. Fructose hypothesis: the fructose component common to all major caloric 
sweeteners (sucrose, high-fructose corn syrup, honey, and fruit juice 




cardiovascular disease, hypertension, diabetes, cancer, and nonalcoholic fatty 
liver disease. [210] 
6. Adiposity hormones: Hormones that circulate in direct proportion to body fat 
and convey the state of total energy stores to the CNS. [52] 
7. Satiety: The state of feeling full to the point of satisfaction after the 
consumption of food. [52] 
8. Neuropeptide: A small protein-like molecule that is used by neurons to 
communicate with each other, often in a paracrine manner. [52] 
9. Neurotransmitters: Chemical messengers that are released by the end of a 
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